Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis

Cancer Biology and Therapy

Volumn 4, Issue 10, 2005, Pages 1154-1158

  Belova, Galina I ^a   Demidov, Oleg N ^a,b   Fornace Jr , Albert J ^a,c   Bulavin, Dmitry V ^b,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d NONE   (Singapore)

Author keywords

Cancer; Inhibitors; Suppression; Therapy; Tumorigenesis; Wip1 phosphatase

Indexed keywords

DOXORUBICIN; PHOSPHATASE; PROTEIN INHIBITOR; PROTEIN SUBUNIT;

ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL LINE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME INHIBITION; FEMALE; MOUSE; NONHUMAN; ONCOGENE; TRANSGENIC MOUSE; XERORADIOGRAPHY;

EID: 27744481299     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.10.2204     Document Type: Article

References (17)

1. Kelland LR. Small molecule anticancer drugs. IDrugs 1999; 2:550-2.
2. Sudbeck EA, Uckun FM. Recent advances in JAK3 kinase inhibitors. IDrugs 1999; 2:1026-30.
3. Strumberg D, Seeber S. Raf kinase inhibitors in oncology. Onkologie 2005; 28:101-7.
4. Pearson MA, Fabbro D. Targeting protein kinases in cancer therapy: A success? Expert Rev Anticancer Ther 2004; 4:1113-24.
5. Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE, Vande Woude GF, O'Connor PM, Appella E. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA 1997; 94:6048-53.
6. Takekawa M, Adachi M, Nakahata A, Nakayama I, Itoh F, Tsukuda H, Taya Y, Imai K. p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 2000; 19:6517-26.
7. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, Kallioniemi A, Fornace Jr AJ, Appella E. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 2002; 31:210-5.
8. Li J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KC, Gabriele T, McCurrach ME, Marks JR, Hoey T, Lowe SW, Powers S. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet. 2002; 31:133-4.
9. Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T, Inazawa J. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 2003; 63:1876-83.
10. Hirasawa A, Saito-Ohara F, Inoue J, Aoki D, Susumu N, Yokoyama T, Nozawa S, Inazawa J, Imoto I. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets.Clin Cancer Res 2003; 9:1995-2004.
11. Bulavin DV, Fornace AJ. p38 MAP kinase's emerging role as a tumor suppressor. Klein and Vande Woude, eds. Advances in Cancer Research. Elsevier Publishers, 2004:92:95-118.
12. Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, Anderson CW, Appella E, Fornace Jr AJ. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet 2004; 36:343-50.
13. Bernards R. Wip-ing out cancer. Nat Genet 2004; 36:319-20.
14. Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E, Fornace Jr AJ. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 1999; 18:6845-54.
15. Harrison M, Li J, Degenhardt Y, Hoey T, Powers S. Wip1-deficient mice are resistant to common cancer genes. Trends Mol Med 2004; 10:359-61.
16. Brancho D, Tanaka N, Jaeschke A, Ventura JJ, Kelkar N, Tanaka Y, Kyuuma M, Takeshita T, Flavell RA, Davis RJ. Mechanism of p38 MAP kinase activation in vivo. Genes Dev 2003; 17:1969-78.
17. Yamaguchi H, Minopoli G, Demidov ON, Chatterjee DK, Anderson CW, Durell SR, Appella E. Substrate specificity of the human protein phosphatase 2Cdelta, Wip1. Biochemistry 2005; 44:5285-94.